Mechanisms of resistance to CDK4/6 inhibitors in HR+ HER2- breast cancer

Resistance Mechanisms Overview

Resistance to CDK4/6 inhibitors in HR+ HER2- breast cancer occurs through several mechanisms, including:

• Pathway bypass mechanisms (e.g., PI3K/AKT/mTOR, RAS, FGFR, MAPK activation)
• Cell cycle alterations (e.g., cyclin E-CDK2 activation, AURKA amplification, RB1 loss)
• ESR1 mutations

These mechanisms account for 66-80% of resistant tumors, affecting 10-20% of patients at treatment initiation and most others developing acquired resistance after 24-28 months.

Abstract

Eight major mechanisms collectively account for 66-80% of resistant tumors:

• AURKA amplification: 26.8%
• CCNE2 amplification: 14.6%
• AKT1 alterations: 12.2%
• Cell cycle-specific alterations (e.g., RB1 loss affecting 9.8% of cases)
• Pathway bypass mechanisms (e.g., RAS activation affecting 9.8%)
• ESR1 mutations: Occur in up to 30% of cases as acquired resistance.

Methods

We analyzed 10 sources focusing on:

• HR+ HER2- Breast Cancer Population
• CDK4/6 Inhibitor Treatment
• Resistance Mechanisms Focus
• Appropriate Study Design
• Clinical Relevance
• Breast Cancer Subtype Specificity
• Cancer Type Specificity
• Publication Quality

Data Extraction

• Resistance Mechanisms:
  • RB1 Loss and Alterations: 9.8%
  • Cyclin E-CDK2 Pathway Activation: Present in 14.6%
  • CDK Amplification (CDK4 & CDK6)
  • INK4 Family Alterations
  • AURKA Amplification: 26.8%
  • PI3K/AKT/mTOR Pathway Activation: Present in 12.2%
  • RAS Activation: 9.8%
  • FGFR Pathway Activation: 7.3%
  • MAPK Pathway Activation: 12.2%
  • ESR1 mutations: up to 30%

Resistance Prevalence and Timeline

Approximately 10% of patients exhibit de novo resistance to CDK4/6 inhibitors, while up to 20% of tumors show intrinsic resistance. Acquired resistance typically develops after 24-28 months of first-line therapy, while some resistance mechanisms can appear as quickly as 72 hours post-treatment initiation.

Therapeutic Implications

Various treatment strategies targeting specific resistance mechanisms include:

• Combination therapies (e.g., dual inhibition strategies for cyclin E-driven resistance)
• PI3K/AKT/mTOR pathway inhibitors
• AURKA inhibitors for AURKA-amplified tumors
• Oral SERDs for ESR1 mutations

Biomarkers for Resistance

Several biomarkers were identified to assess resistance mechanisms:

• Predictive Biomarkers: RB loss, cyclin E overexpression, ESR1 mutations, gBRCA mutations, PIK3CA hotspot mutations, MYC genomic alterations.
• Monitoring Biomarkers: Elevated phospho-AKT levels, ESR1 mutations via liquid biopsies, ctDNA dynamics.

Synthesis

The research highlights substantial heterogeneity in resistance mechanisms to CDK4/6 inhibitors in HR+ HER2- breast cancer. Notably, AURKA amplification is the most frequent alteration. Clinical validation of mechanisms through extensive genomic profiling and preclinical data presents opportunities for targeted therapy enhancements in future treatment protocols.